Thomas Stratford
Direktor/Vorstandsmitglied bei Kyowa Kirin International Plc
Profil
Thomas Stratford is currently a Director at Kyowa Kirin International Plc.
He previously worked as a Principal at GSK Plc.
Dr. Stratford holds a doctorate degree from King's College London.
Aktive Positionen von Thomas Stratford
| Unternehmen | Position | Beginn |
|---|---|---|
Kyowa Kirin International Plc
 Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Thomas Stratford
| Unternehmen | Position | Ende |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | - |
Ausbildung von Thomas Stratford
| King's College London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GSK PLC | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Health Technology |
